Source-grounded facts extracted from Aveanna Healthcare Holdings, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Dr. Erica Schwartz resigned as Director at Aveanna Healthcare Holdings, Inc..
“On August 5, 2026, Dr. Erica Schwartz, a Class III director of Aveanna Healthcare Holdings Inc. (the "Company"), notified the Company of her decision to resign from the Company's Board of Directors, effective immediately, in connection with her nomination and subsequent confirmation as the Director of the United States Centers of Disease Control and Prevention.”
Aveanna Healthcare Holdings, Inc. shareholders approved Approval of a non-binding advisory resolution approving the compensation of the Company’s named executive officers as disclosed in the Company’s 2026 Proxy Statement for the Annual Meeting at the 2026-05-29 meeting.
“Proposal 3: Approval of a non-binding advisory resolution approving the compensation of the Company’s named executive officers as disclosed in the Company’s 2026 Proxy Statement for the Annual Meeting: Votes Votes Broker For Against Abstentions Non-Votes 160,094,458 19,490,871 61,105 19,773,305”
Aveanna Healthcare Holdings, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending January 2, 2027 at the 2026-05-29 meeting.
“Proposal 2: Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending January 2, 2027: Votes Votes Broker For Against Abstentions Non-Votes 198,808,170 477,379 134,190 -”
Aveanna Healthcare Holdings, Inc. shareholders approved Election of the three Class II directors to the Board of Directors for three-year terms expiring at the 2029 Annual Meeting at the 2026-05-29 meeting.
“Proposal 1: Election of the three Class II directors to the Board of Directors of the Company for three-year terms expiring at the Company’s 2029 Annual Meeting of Stockholders: Votes Votes Broker Director For Withheld Non-Votes Rodney D. Windley 150,079,425 29,567,009 19,773,305 Sam Weil 160,026,278 19,620,156 19,773,305 Steven E. Rodgers 168,380,101 11,266,333 19,773,305”
Aveanna Healthcare Holdings, Inc. reported First Quarter ended April 4, 2026 results: revenue $647.9 million, net income $41.7 million, EPS $0.19. Guidance raised.
“First Quarter Revenue was $647.9 million, a 15.9% increase over the prior year period • First Quarter Net income was $41.7 million compared to $5.2 million for the prior year period”
Aveanna Healthcare Holdings, Inc. reported three-month period ended January 3, 2026 results: revenue $662.5 million, net income $178.8 million, EPS $0.80 per diluted share. Guidance reaffirmed.
“Revenue was $662.5 million for the three-month period ended January 3, 2026, as compared to $519.9 million for the three-month period ended December 28, 2024, an increase of $142.6 million, or 27.4%. The overall increase in revenue was attributable to a $118.5 million increase in PDS segment revenue, a $14.9 million increase in HHH segment revenue, and a $9.2 million increase in MS segment revenue compared to the fourth quarter of 2024. Gross margin was $213.3 million, or 32.2% of revenue, for the three-month period ended January 3, 2026, as compared to $171.7 million, or 33.0% of revenue, for the three-month period ended December 28, 2024, an increase of $41.6 million, or 24.2%. Net income was $178.8 million for the three-month period ended January 3, 2026, as compared to net income of $29.2 million for the three-month period ended December 28, 2024. Net income per diluted share was $0.80 for the three-month period ended January 3, 2026, as compared to net income per diluted share of”
Aveanna Healthcare Holdings, Inc. incurred term loan of $1,325,000,000 at Term SOFR plus an applicable margin equal to 3.75% per annum or a base rate plus maturing September 17, 2032.
“The Refinancing Amendment additionally provides for the refinancing of the Existing Term Loans ("2025 Refinancing Term Loans") under the Existing Term Loan Facility (the "2025 Refinancing Term Facility") and an incremental senior secured term loan facility (the "2025 Incremental Term Facility"), with aggregate commitments increased by $439,050,000 (the "2025 Incremental Term Loans"). Combined, the 2025 Refinancing Term Loans and 2025 Incremental Term Loans aggregate to a total principal balance of $1,325,000,000 (the "2025 Term Loans")”
Aveanna Healthcare Holdings, Inc. incurred revolving credit of $250,000,000 at Term SOFR plus an applicable margin equal to 3.75% per annum or a base rate plus maturing September 17, 2030.
“Existing Credit Agreement and incremental revolving loan commitments in an aggregate principal amount of $79,670,000, resulting in total aggregate revolving loan commitments of $250,000,000 (the "2025 Refinancing Revolving Credit Facility"), a portion of which may be used for the issuance of letters of credit and swingline loans. The Refinancing Amendment”
Sheldon Retchin resigned as Director at Aveanna Healthcare Holdings, Inc..
“On March 27, 2025, and with immediate effect, Dr. Sheldon Retchin, a Class III Director of Aveanna Healthcare Holdings Inc., a Delaware corporation (the "Company"), notified the Company of his resignation from the Company's Board of Directors for personal health reasons.”
Brent Layton was appointed as Class III director and member of the Audit Committee at Aveanna Healthcare Holdings, Inc..
“On November 1, 2024, the Board of Directors (the “Board”) of Aveanna Healthcare Holdings Inc. (the “Company”) appointed Brent Layton to serve as a Class III director and as a member of the Audit Committee of the Board (the “Audit Committee”), to fill a vacancy.”
Aveanna Healthcare Holdings, Inc. shareholders approved Approval of a non-binding advisory resolution approving the compensation of the Company's named executive officers as disclosed in the Company's 2024 Proxy Statement for the Annual Meeting at the 2024-05-16 meeting.
“Proposal 3: Approval of a non-binding advisory resolution approving the compensation of the Company's named executive officers as disclosed in the Company's 2024 Proxy Statement for the Annual Meeting: Votes Votes Broker For Against Abstentions Non-Votes 169,424,014 119,091 21,953 8,364,952”
Aveanna Healthcare Holdings, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 28, 2024 at the 2024-05-16 meeting.
“Proposal 2: Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 28, 2024: Votes Votes Broker For Against Abstentions Non-Votes 177,333,031 94,541 502,438 0”
Aveanna Healthcare Holdings, Inc. shareholders approved Election of three Class III directors at the 2024-05-16 meeting.
“Proposal 1: Election of three Class III directors to the Board of Directors of the Company for three-year terms to hold office until the Company's 2027 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Votes Votes Broker Director For Withheld Non-Votes Sheldon M. Retchin 164,264,106 5,300,876 8,365,028 Erica G. Schwartz 168,460,462 1,104,520 8,365,028 Jeff Shaner 163,330,989 6,230,969 8,368,052”
Aveanna Healthcare Holdings, Inc. reported three-month period ended March 30, 2024 results: revenue $490.7 million, net income Net loss was $11.2 million, EPS $(0.06) per diluted share. Guidance raised.
“--- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 AVEANNA HEALTHCARE HOLDINGS ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS AND REVISED 2024 OUTLOOK • First Quarter Revenue was $490.7 million, a 5.2% increase over the prior year o Gross margin increased 1.0% to $145.9 million, compared to Q1 2023 • First Quarter Net loss was $11.2 million, compared to net loss of”
Shannon Drake departed as Chief Legal Officer and Secretary at Aveanna Healthcare Holdings, Inc..
“On January 15, 2024, Aveanna Healthcare Holdings Inc, a Delaware corporation (the “Company”), its wholly owned subsidiary, Aveanna Healthcare LLC, and Shannon Drake, the Company’s Chief Legal Officer and Secretary, entered into a Separation and Transition Agreement (the “ Separation Agreement ”), pursuant to which Mr. Drake’s employment with the Company and his tenure as Chief Legal Officer and Secretary will terminate on March 31, 2024”
Matthew Buckhalter was appointed as Chief Financial Officer and Principal Financial Officer at Aveanna Healthcare Holdings, Inc..
“On December 11, 2023, the Company's board of directors (the "Board") appointed Matthew Buckhalter, the Company's current Interim Chief Financial Officer and Principal Financial Officer to Chief Financial Officer and Principal Financial Officer, effective January 1, 2024.”
Aveanna Healthcare Holdings, Inc. reported three and nine-month periods ended September 30, 2023 results: revenue $478.0 million, net income Net loss was $102.4 million, EPS Net loss per diluted share was $(0.54). Guidance raised.
“by reference in this Item 2.02. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 AVEANNA HEALTHCARE HOLDINGS ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS • Revenue was $478.0 million, a 7.9% increase over the prior year o Gross margin increased 9.4% to $147.3 million, compared to Q3 2022 • Net loss was $102.4 million, inclusive of a $105.1 million non-cash”
Aveanna Healthcare Holdings, Inc. reported three and six-month periods ended July 1, 2023 results: revenue $471.9 million, net income $25.6 million, EPS $0.13. Guidance raised.
“Revenue was $471.9 million, a 6.5% increase over the prior year o Gross margin increased 7.0% to $155.3 million, compared to Q2 2022 • Net income was $25.6 million, compared to net loss of $473.9 million in the comparable prior year period o Adjusted EBITDA was $35.8 million, a sequential increase of 25.6% and a 3.2% decrease as compared to the prior year • Full year 2023 revenue guidance raised to a range of $1,850 million to $1,860 million o Full year 2023 Adjusted EBITDA guidance raised to a range of $132 million to $135 million”
Debbie Stewart was appointed as Senior Vice President and Principal Accounting Officer at Aveanna Healthcare Holdings, Inc..
“On June 14, 2023, the Board appointed Debbie Stewart, the Company’s current Vice President and Chief Accounting Officer, as Senior Vice President and the Company’s Principal Accounting Officer, effective July 7, 2023.”
Matthew Buckhalter was appointed as Interim Chief Financial Officer and Principal Financial Officer at Aveanna Healthcare Holdings, Inc..
“On June 14, 2023, the Company’s board of directors (the “Board”) appointed Matthew Buckhalter, the Company’s current Senior Vice President of Finance, as Interim Chief Financial Officer and the Company’s Principal Financial Officer, effective July 7, 2023.”
David Afshar resigned as Chief Financial Officer at Aveanna Healthcare Holdings, Inc..
“On June 9, 2023, David Afshar notified Aveanna Healthcare Holdings Inc., a Delaware corporation (the “Company” or “Aveanna”), of his resignation from his position as Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer), effective July 7, 2023.”
Aveanna Healthcare Holdings, Inc. shareholders approved Approval of an amendment to the Company’s Charter to effect a Reverse Stock Split with respect to the Company’s issued and outstanding common stock at any time prior to December 29, 2023, within a pre-approved ratio Range (1 for 5 to 1 for 20) at the 2023-05-10 meeting.
“Proposal 4: Approval of an amendment to the Company’s Charter, in the form set forth in Appendix A of the Proxy Statement, to effect a Reverse Stock Split with respect to the Company’s issued and outstanding common stock at any time prior to December 29, 2023, within a pre-approved ratio Range (1 for 5 to 1 for 20), with the Effective Ratio to be a ratio within the Range to be determined at the discretion of the Company’s Board of Directors and included in a public announcement by the Company before the effectiveness of the Reverse Stock Split: Votes Votes Broker For Against Abstentions Non-Votes 176,081,717 2,496,049 42,765 0”
Aveanna Healthcare Holdings, Inc. shareholders approved Approval of a non-binding advisory resolution approving the compensation of the Company’s named executive officers as disclosed in the Company’s 2023 Proxy Statement for the Annual Meeting at the 2023-05-10 meeting.
“Proposal 3: Approval of a non-binding advisory resolution approving the compensation of the Company’s named executive officers as disclosed in the Company’s 2023 Proxy Statement for the Annual Meeting: Votes Votes Broker For Against Abstentions Non-Votes 168,402,819 1,910,610 595,313 7,711,789”
Aveanna Healthcare Holdings, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 30, 2023 at the 2023-05-10 meeting.
“Proposal 2: Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 30, 2023: Votes Votes Broker For Against Abstentions Non-Votes 178,546,739 22,205 51,587 0”
Aveanna Healthcare Holdings, Inc. shareholders approved Election of three Class I directors to the Board of Directors for three-year terms at the 2023-05-10 meeting.
“Proposal 1: Election of three Class I directors to the Board of Directors of the Company for three-year terms to hold office until the Company’s 2026 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Votes Votes Broker Director For Withheld Non-Votes Rodney D. Windley 158,576,161 12,332,581 7,711,789 Christopher R. Gordon 163,952,678 6,956,064 7,711,789 Steven E. Rodgers 167,606,343 3,302,399 7,711,789”
Aveanna Healthcare Holdings, Inc. reported first quarter 2023 (three-month period ended April 1, 2023) results: revenue $466.4 million, net income -$32.0 million, EPS -$0.17. Guidance reaffirmed.
“in this Item 2.02. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 AVEANNA HEALTHCARE HOLDINGS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS • Revenue increased 3.5% to $466.4 million, compared to Q1 2022 o Gross margin decreased 0.2% to $144.5 million, compared to Q1 2022 • Net loss was $32.0 million, compared to net income of $25.3 million in Q1 2022 o”
Aveanna Healthcare Holdings, Inc. reported the three-month period ended December 31, 2022 results: revenue $451.1 million, net income $237.8 million, EPS $1.28.
“Revenue was $451.1 million for the three-month period ended December 31, 2022”
Aveanna Healthcare Holdings, Inc. reported the fiscal year ended December 31, 2022 results: revenue $1,787.6 million, net income $662.0 million, EPS $3.57.
“Revenue was $1,787.6 million for the fiscal year ended December 31, 2022”
Aveanna Healthcare Holdings, Inc. reported the three-month period and fiscal year ended December 31, 2022 results: revenue $451.1 million, net income $237.8 million, EPS $1.28.
“Item 2.02. --- EX-99 (EX-99.1) --- EX-99 Exhibit 99.1 AVEANNA HEALTHCARE HOLDINGS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS • Revenue increased 9.0% to $451.1 million, compared to Q4 2021 o Gross margin increased 3.5% to $128.8 million, compared to Q4 2021 • Net loss was $237.8 million, compared to net loss of $126.2 million in Q4 2021 o”
Aveanna Healthcare Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“December 23, 2022, Aveanna Healthcare Holdings Inc., a Delaware corporation (the "Company"), received written notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company, that based on the closing bid price of the Company's common stock, par value $0.01 per share (the "Common Stock"), for the last 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (the "”
Aveanna Healthcare Holdings, Inc. shareholders approved non-binding advisory vote regarding the frequency of future stockholder non-binding advisory votes on the compensation of the Company's named executive officers at the 2022-05-10 meeting.
“At the Annual Meeting of Stockholders of the Company held on May 10, 2022 (the “ Annual Meeting ”), the Company’s stockholders voted on, among other matters, a non-binding advisory vote regarding the frequency of future stockholder non-binding advisory votes on the compensation of the Company’s named executive officers. The frequency of one year received the highest number of votes cast by stockholders at the Annual Meeting.”
Jeff Shaner was appointed as Chief Executive Officer and Director at Aveanna Healthcare Holdings, Inc..
“The Company appointed Jeff Shaner, its current Chief Operations Officer (“COO”), to serve as the Company’s CEO and Director, effective December 31, 2022.”
Anthony H. Strange resigned as Chief Executive Officer and Director at Aveanna Healthcare Holdings, Inc..
“Tony Strange Resignation and Jeff Shaner’s Appointment as Chief Executive Officer and Director On December 13, 2022, Aveanna Healthcare Holdings Inc. (the “Company”) announced that its Chief Executive Officer (“CEO”) and Director, Anthony H. Strange, is separating from employment with the Company, effective December 31, 2022.”
Aveanna Healthcare Holdings, Inc. reported three and nine-month periods ended October 1, 2022 results: revenue $1,336.5 million.
“Revenue was $443.0 million for the three-month period ended October 1, 2022, as compared to $411.3 million for the three-month period ended October 2, 2021, an increase of $31.7 million, or 7.7%.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.